GlassScriptPhysician profile
Kimberly Hayes
NPI 1467448878
$13,821.16
in general payments reported to CMS, 2019-2025
66 companies · $2,636 in 2025
The $2,636 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,299 · 2022: $2,974 · 2023: $2,882 · 2024: $3,031 · 2025: $2,636.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,442 · Education: $107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,442.09 |
| Education | $106.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,500.16 | 2021-2025 | |
| Novo Nordisk INC | $1,314.06 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,102.13 | 2021-2025 | Airsupra, Breztri, Bevespi Aerosphere |
| Glaxosmithkline, LLC. | $844.38 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $738.80 | 2021-2025 | Mounjaro, Zepbound, Emgality |
| Amgen INC. | $705.59 | 2021-2025 | Otezla, Repatha, Evenity |
| Lundbeck LLC | $448.20 | 2022-2025 | Rexulti |
| Sanofi-Aventis U.S. LLC | $442.33 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $425.56 | 2021-2025 | Xarelto, Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $394.53 | 2022-2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $356.75 | 2021-2025 | Jardiance |
| Astellas Pharma US INC | $286.81 | 2022-2025 | Veozah, Myrbetriq |
| Vanda Pharmaceuticals INC. | $284.80 | 2021-2025 | Fanapt |
| Otsuka America Pharmaceutical, INC. | $266.32 | 2021-2025 | Rexulti |
| Exact Sciences Corporation | $262.19 | 2023-2025 | Cologuard Collection Kit |
Show all 66 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Hayes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.